Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Business Officer | February 02, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2026-02-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 20,000 · Balance 20,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. F2: Includes 20,000 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 · Expires 2036-02-01 | Direct | 50,000 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 50,000 · Balance 50,000 F3: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
| Performance Stock Units (PSUs)SEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2026-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-02 · Grant · Acquired 50,000 · Balance 50,000 F4: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.
F2: Includes 20,000 RSUs.
F3: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F4: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 16:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000043 · form4.xml · derivative · entry 3 Lester Rachael · CIK 0002094324 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F4 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F4 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001610717-26-000043 · form4.xml · derivative · entry 2 Lester Rachael · CIK 0002094324 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-02-01 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000043 · form4.xml · nonDerivative · entry 1 Lester Rachael · CIK 0002094324 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Includes 20,000 RSUs. Read SEC document |
| October 20, 2025 Filed Oct 29, 2025 16:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000370 · form4.xml · derivative · entry 1 Lester Rachael · CIK 0002094324 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-10-19 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary measured from October 20, 2025 (the "Vesting Commencement Date"), and 1/48th of the shares will vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.